GSKH — Precidian ETFs Trust - GSK plc ADRhedged (ETF)

Price: $70.67 · 1 day: -1.11% · 5 days: +0.05% · 1 month: -1.25% · YTD: +3.61%
As of 2026-09-23 13:49 UTC.

52-week range: $56.03 – $85.03 (currently at 50% of the range).

The read

GSKH is in a downtrend, momentum firm. $70.93 is the level overhead; $70 the first support below.

3 of 6 technical checks lean bearish.

Price vs 50-day: below
Price vs 200-day: below
50d vs 200d avg: below
MACD: bullish
RSI momentum: 51
5-day tape: +0.0%

Trend	Downtrend · below 50-day & below 200-day
Momentum	RSI 51.07 · neutral · MACD bullish
Trend strength	ADX 11.4 · weak or range
Location	-0.4% vs 50-day MA
52-week range	-17% from high · +25% from low
Volatility	ATR 1.1 · ~1.6%/day

Key levels

Level	Type	Distance
$70.93 (resistance)	sma 50	0.37%
$71.35 (resistance)	swing zone	0.97%
$73.01 (resistance)	swing zone	3.31%
$70.0 (support)	round	-0.95%
$68.97 (support)	swing zone	-2.4%
$60.0 (support)	round	-15.1%

Indicators

RSI (14)	51.07	MACD	0.0027
ADX (14)	11.4	ATR (14)	1.1
50-day average	$70.93	200-day average	$73.23

Latest GSKH news

Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight — The global nephrotic syndrome market, valued at approximately USD 400 million in 2025 across seven major markets, is projected to experience robust growth through 2036, driven by rising prevalence of kidney disorders and (PR Newswire, 2026-06-29)
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? — Law firm Halper Sadeh LLC announced investigations into pending acquisitions of Nuvalent, Inc. (NASDAQ: NUVL), Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), and Taylor Morrison Home Corporation (NYSE: TMHC) for potentia (PR Newswire, 2026-06-25)
MRM Health Strengthens Board with Michel Detheux as Chairman and Hans-Jürgen Wörle as Independent Director as MH002 Advances Through Phase 2b — 阅读阅读好部分好大大啊部分好部分啊部分好部分好部分好好好部分好大一些阅读一些阅读一些说明一下部分部分部分部分啊部分好部分什么部分什么部分什么部分怎么样啊好看详细介绍版介绍部分什么部分什么部分什么部分什么部分什么部分怎么样，部分什么部分好部特别学习阅读阅读介绍列表阅读全部部分部分部分啊部分什么内容一下部分部分部分一些阅读啊专业部分什么部分什么部分什么部分等等特别专业什么部分什么部分什么部分什么部分等等需要专业部部分部分好特别这个经过一些阅 (Business Wire, 2026-06-25)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, NUVL, AXTA, and PFLC — Monteverde & Associates PC has announced investigations into four pending mergers and acquisitions on behalf of shareholders. The transactions include Taylor Morrison Home Corp.'s (NYSE: TMHC) $72.50 per share cash sale (PR Newswire, 2026-06-24)
Are ROKU, SLP, NUVL, DAN Obtaining Fair Deals for their Shareholders? — Halper Sadeh LLC, an investor rights law firm, announced investigations into four proposed corporate transactions to determine whether shareholders are receiving fair consideration. The transactions include Roku's sale t (PR Newswire, 2026-06-22)
Biond Biologics Appoints Giovanni Selvaggi, M.D., as Chief Medical Officer ("CMO") — Biond Biologics announced the appointment of Giovanni Selvaggi, M.D. as Chief Medical Officer, bringing over 30 years of oncology experience and a track record of advancing cancer therapies to regulatory approval. Dr. Se (PR Newswire, 2026-06-22)
Are NUVL, DAN, PAYO Obtaining Fair Deals for their Shareholders? — Investor rights law firm Halper Sadeh LLC has initiated investigations into the pending acquisitions of Nuvalent, Inc. (NASDAQ: NUVL), Dana Incorporated (NYSE: DAN), and Payoneer Global Inc. (NASDAQ: PAYO) regarding pote (PR Newswire, 2026-06-18)
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) — GSK plc and Spero Therapeutics announced that the U.S. Food and Drug Administration has approved Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infecti (Business Wire, 2026-06-17)

Explore more

Interactive GSKH chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs